Are Angiotensin Converting Enzyme and von Willebrand factor circulating levels useful surrogate parameters to monitor disease activity in Kawasaki disease?

To verify if Angiotensin Converting Enzyme (ACE) and von Willebrand factor (vWF) may be used as a laboratory marker for the follow-up of endothelial derangement and therapeutic efficacy in Kawasaki disease (KD), circulating ACE, vWF routine hematological tests and cardiac involvement were assessed in 32 children with established diagnosis of KD before and up to six months after intravenous gamma-globulins (i.v.IG) treatment. I.v.IG treatment normalized progressively all the hematological parameters to levels comparable with healthy controls within 30 days. At baseline, ACE levels resulted significantly lower (1.8 +/- 1.3 pmol/ml/min), and vWF levels significantly increased (210.3 +/- 35.2%) when compared with controls (respectively 7.0 +/- 0.9 pm/ml/min and 99 +/- 17.9%). Seven days after the treatment vWF levels were decreased (188 +/- 18.4%) but still significantly higher than controls, and fully normalized after 15 days (104.8 +/- 14.3%). ACE levels were found progressively increased at 7, 15, and 30 days after the treatment (respectively 2.7 +/- 1.0, 3.7 +/- 0.4, 5.04 +/- 0.9 pm/ml/min) and reached the range of normality only after two months (7.74 +/- 2.46 pm/ml/min). The present study shows that ACE and vWF circulating levels are significantly modified during the acute phase of the disease.

[1]  M. Cerinic,et al.  Clinical and Laboratory Features and Disease Outcome of Kawasaki Disease: The Analysis of Our Experience and Literature Review , 1997, Journal of clinical rheumatology.

[2]  S. Sato,et al.  High incidence of angiotensin I converting enzyme genotype II in Kawasaki disease patients with coronary aneurysm , 1997, European Journal of Pediatrics.

[3]  S. Kaveri,et al.  Mechanisms of action of intravenous immune globulin in immune‐mediated diseases , 1996, Clinical and experimental immunology.

[4]  M. Matucci-Cerinic,et al.  The central role of the endothelium in the pathogenesis of vasculitides. , 1995, International angiology : a journal of the International Union of Angiology.

[5]  E. Nabel,et al.  Fibroblast growth factor stimulates angiotensin converting enzyme expression in vascular smooth muscle cells. Possible mediator of the response to vascular injury. , 1995, The Journal of clinical investigation.

[6]  M. Matucci-Cerinic,et al.  Angiotensin converting enzyme a new tool for the follow-up of endothelial injury in paediatric vasculitides. , 1994, British journal of rheumatology.

[7]  D. Harrison,et al.  Regulation of endothelial nitric oxide synthase mRNA, protein, and activity during cell growth. , 1994, The American journal of physiology.

[8]  E. Vicaut,et al.  ACE in three tunicae of rat aorta: expression in smooth muscle and effect of renovascular hypertension. , 1994, The American journal of physiology.

[9]  S. Trapani,et al.  Efficacy and safety of immunoglobulin retreatment in Kawasaki disease. , 1994, The Journal of pediatrics.

[10]  R. Petty,et al.  Diagnostic value of anti-neutrophil cytoplasmic and anti-endothelial cell antibodies in early Kawasaki disease. , 1994, The Journal of pediatrics.

[11]  J. Krieger,et al.  Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis. , 1994, The Journal of clinical investigation.

[12]  S. Feman,et al.  Serum angiotensin converting enzyme in diabetic patients. , 1993, The American journal of the medical sciences.

[13]  P. Pelkonen,et al.  Intravenous Immune Globulin Reduces the IgG Antiendothelial Cell Antibody Response in Kawasaki Disease , 1993 .

[14]  A. Jaffa,et al.  Angiotensin converting enzyme: an in vivo and in vitro marker of endothelial injury. , 1992, The Journal of laboratory and clinical medicine.

[15]  F. Rojo,et al.  von Willebrand factor antigen in hypertrophic osteoarthropathy. , 1992, The Journal of rheumatology.

[16]  M Takahashi,et al.  A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. , 1991, The New England journal of medicine.

[17]  P Corvol,et al.  An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. , 1990, The Journal of clinical investigation.

[18]  M. Matucci-Cerinic,et al.  Reduced angiotensin converting enzyme plasma activity in scleroderma. A marker of endothelial injury? , 1990, The Journal of rheumatology.

[19]  L. Drouet,et al.  Serum angiotensin-converting enzyme: an endothelial cell marker. Application to thromboembolic pathology. , 1988, The Journal of laboratory and clinical medicine.

[20]  H. Kato,et al.  Kawasaki disease: cardiac problems and management. , 1988, Pediatrics in review.

[21]  A. Woolf,et al.  Factor VIII related antigen in the assessment of vasculitis. , 1987, Annals of the rheumatic diseases.

[22]  H. Kato,et al.  Myocardial infarction in Kawasaki disease: clinical analyses in 195 cases. , 1986, The Journal of pediatrics.

[23]  A. Federici,et al.  Increased von Willebrand factor antigen in the plasma of patients with vasculitis. , 1984, Arthritis and rheumatism.

[24]  O. Schmitz,et al.  Angiotensin-converting enzyme activity in renal disorders: influence of disease pattern, hemodialysis and transplantation. , 1984, Clinical nephrology.

[25]  M. Kahaleh,et al.  Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. , 1981, Annals of internal medicine.

[26]  B. Seegal,et al.  Angiotensin-converting enzyme: vascular endothelial localization. , 1976, Science.